Effects of Valsartan on Inflammatory and Oxidative Stress Markers in Hypertensive, Hyperglycemic Patients: An Open-Label, Prospective Study

Current Therapeutic Research - Clinical and Experimental

Volumn 68, Issue 5, 2007, Pages 338-348

  Kuboki, Koji ^a   Iso, Kaoru ^a   Murakami, Eiichi ^a   Abe, Seiko ^b   Araki, Emi ^b   Ueshiba, Hajime ^a   Yoshino, Gen ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitsubishi Kagaku Bio Clinical Laboratories Inc   (Japan)

Author keywords

diabetes; hypertension; inflammatory marker; oxidative stress marker; valsartan

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 18; INTERLEUKIN 6; L SELECTIN; SULFONYLUREA; VALSARTAN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC DIET; DIABETIC HYPERTENSION; DISEASE MARKER; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INDUCED HEADACHE; FEMALE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MALE; MEDICAL ASSESSMENT; MYALGIA; NAUSEA; OUTPATIENT DEPARTMENT; OXIDATIVE STRESS; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAMPLE SIZE; STOMACH PAIN; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 37349109222     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2007.10.008     Document Type: Article

References (29)

1. Kannel W., and McGee D. Diabetes and cardiovascular disease. The Framingham study. JAMA 241 (1979) 2035-2038
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
3. Definition and the diagnostic standard for metabolic syndrome-Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. [in Japanese]. Nippon Naika Gakkai Zasshi 94 (2005) 794-809
4. Turnbull F., and for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
5. Staessen J., Wang J., and Thijs L. Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. J Hypertens 21 (2003) 1055-1076
6. Rakugi H., and Ogihara T. Guidelines for treatment of hypertension: JSH2004. Nippon Ronen Igakkai Zasshi 43 (2006) 569-573
7. Dzau V. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77 (1988) I4-I13
8. Shiuchi T., Iwai M., Li H., et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43 (2004) 1003-1010
9. Chan P., Wong K., Liu I., et al. Antihyperglycemic action of angiotensin II recep- tor antagonist, valsartan, in streptozotocin-induced diabetic rats. J Hypertens 21 (2003) 761-769
10. Dzau V. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 37 (2001) 1047-1052
11. Cheng Z., Vapaatalo H., and Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 11 (2005) RA194-RA205
12. for the Val-MARC Investigators. Ridker P., Danielson E., Rifai N., et al. Valsartan, blood pressure reduction, and C-reactive protein: Primary report of the Val-MARC trial. Hypertension 48 (2006) 73-79
13. Saisho Y., Komiya N., and Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan. Diabetes Res Clin Pract 74 (2006) 201-203
14. Ogawa S., Mori T., Nako K., et al. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertens 47 (2006) 699-705
15. Ledue T., Weiner D., Sipe J., et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 35 (1998) 745-753
16. Proudfoot J., Barden A., Mori T., et al. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-a comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem 272 (1999) 209-215
17. Erhola M., Toyokuni S., Okada K., et al. Biomarker evidence of DNA oxidation in lung cancer patients: Association of urinary 8-hydroxy-2Ldeoxyguanosine excretion with radiotherapy, chemotherapy, and response to treatment. FEBS Lett 409 (1997) 287-291
18. Sesso H., Buring J., Rifai N., et al. C-reactive protein and the risk of developing hypertension. JAMA 290 (2003) 2945-2951
19. Niskanen L., Laaksonen D., Nyyssonen K., et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 44 (2004) 859-865
20. Rahman S., Lauten W., Khan Q., et al. Effects of eprosartan versus hydrochloro-thiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). Am J Cardiol 89 (2002) 686-690
21. Fliser D., Buchholz K., Hailer H., and for the EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 (2004) 1103-1107
22. Schieffer B., Bunte C., Witte J., et al. Comparative effects of ATl-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44 (2004) 362-368
23. Brasier A., Recinos III A., and Eledrisi M. Vascular inflammation and the reninangiotensin system. Arterioscler Thromb Vasc Biol 22 (2002) 1257-1266
24. Wang C., Li S., Weisel R., et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107 (2003) 1783-1790
25. Griendling K., Minieri C., Ollerenshaw J., and Alexander R. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 (1994) 1141-1148
26. Verma S., Li S., Badiwala M., et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105 (2002) 1890-1896
27. Julius S., Kjeldsen S., Weber M., et al., for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363 (2004) 2022-2031
28. Mochizuki S., Shimizu M., Taniguchi I., et al., for the JIKEI HEART Study Group. JIKEI HEART Study-a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease. Cardiovasc Drugs Ther 18 (2004) 305-309
29. Ogihara T., Saruta T., Matsuoka H., et al. Valsartan in elderly isolated systolic hypertension (VALISH) study: Rationale and design. Hypertens Res 27 (2004) 657-661